Delivery of therapeutic doses of radioiodine using bispecific antibody- targeted bivalent haptens

Journal of Nuclear Medicine

Volumn 39, Issue 11, 1998, Pages 1937-1943

  Gautherot, Emmanuel ^a,b   Le Doussal, Jean Marc ^a   Bouhou, Jamila ^a   Manetti, Corine ^a   Martin, Marie ^a   Rouvier, Eric ^a   Barbet, Jacques ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Immunotech   (France)

Author keywords

Bispecific antibody; Carcinoembryonic antigen; Colon carcinoma; Dosimetry; Pretargeting; Radioimmunotherapy

Indexed keywords

BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIBODY; HAPTEN; MONOCLONAL ANTIBODY; PENTETIC ACID; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; COLON CARCINOMA; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; TARGET ORGAN; TISSUE LEVEL; TUMOR LOCALIZATION;

EID: 0031774254     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Press OW, Eary JF, Appelbaum FR, el al. Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995;346:336-340.
2. 131I-anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-465.
3. Juweid M, Sharkey RM, Behr T, et al. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nucl Med 1996;37:905-911.
4. Behr TM, Sharkey RM, Juweid ME, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 1997;38:858-870.
5. Rosebrough SF. Two-step immunological approaches for imaging and therapy. Quarterly J Nucl Med 1996;40:234-251.
6. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989;30:1358-1366.
7. Le Doussal JM, Gruaz-Guyon A, Martin M, Gautherot E, Delaage M, Barbet J. Targeting of indium-111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res 1990;50:3445-3452.
8. 1 lymphoma with anti-idiotype antibodies: biodistribution kinetics of directly labeled antibodies and bispecific antibody-targeted bivalent haptens. Int J Cancer 1997;71:1000-1009.
9. Le Doussal JM, Chetanneau A, Guyon-Gruaz A, et al. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med 1993;34:1662-1671.
10. 131I-labeled bivalent hapten in patients with medullary thyroid carcinoma and small-cell lung cancer. J Nucl Med 1996;37:1853-1859.
11. 2 antibody containing thioether-linked Fab′g fragments. J Immunol 1987;139:2367-2375.
12. Janevik-Ivanovska E, Gautherot E, Hilairet de Boisferon M, et al. Bivalent hapten peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug Chem 1997;8:526-533.
13. 2, and Fab′ in mice. Cancer Res 1986;46: 3669-3978.
14. Johns HE, Cunningham JR. The physics of radiology. In: Friedmann M, eds. Monograph in the bannerstane division of American lectures in radiation therapy, 3rd ed. Springfield, IL: Charles C. Thomas; 1978:564-574.
15. 2 fragments of monoclonal antiferritin in nude mouse model. J Nucl Med 1993;34:2152-2159.
16. Goodwin DA, Meares CF, David GF, et al. Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals. Nucl Med Biol 1986;13:383-391.
17. 131I-labeled monoclonal antibodies. Cancer Res 1992;52:6036-6044.
18. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JF, Goldenberg DM. Biodistribution and radiation dose estimates for yttrium-and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res 1990;50:2330-2336.
19. Sung C, Van Osdol WW. Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J Nucl Med 1995;36: 867-876.
20. Santos O, Kindle Payne J, Domitrowsky JB, Berkeley C, Mackensen DG. A two step delivery system utilizing a bi-specific monoclonal antibody for radioimmunotherapy. Antibody Immunoconj Radiopharm 1995;8:93-109.
21. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 1995;55:4611-4522.
22. Le Doussal JM, Gautherol E, Martin M, Barbet J, Delaage M. Enhanced in vivo targeting of an asymetric bivalent hapten to double-antigen-positive mouse B cells with monoclonal antibody conjugate cocktails. J Immunol 1991;146:169-175.
23. Goodwill DA, Meares CF, McTigue M, et al. Pretargetred immunoscintigraphy: effect of hapten valency on murine tumor uptake. J Nucl Med 1992;33:2006-2013.
24. Schumacher J, Klivenyi G, Matys R, et al. Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography. Cancer Res 1995;55:115-123.
25. Kranenborg MH, Boerman OC, Oosterwijk-Wakka JC, De Weijert MC, Corstens FH, Oosterwijk E. Two-step radio-immunotargeting of renal cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma x anti-DTPA bispecific monoclonal antibodies. Int J Cancer 1998;75:74-80.
26. Casalini P, Luison E, Menard S, Colnaghi MI, Paganelli G, Canevari S. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J Nucl Med 1997;38:1378-1381.
27. Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991;51:5960-5969.
28. Ratliff B, Reno J, Axworthy D, et al. Performance of antibody streptavidin pretargeting in patients: initial results. J Nucl Med 1995;36:225P.
29. Buchsbaum DJ, Langmuir VK, Wessels BW. Experimental radioimmunotherapy. Med Phys 1993;20:551-567.
30. Devys A, Thedrez P, Gautherot E, et al. Comparative targeting of human colon-carcinoma multicell spheroids using one-and two-step (bispecific antibody) techniques. Int J Cancer 1996;67:883-891.
31. Thames HD, Hendry JH. Radiation-induced injury to tissues. In: Thames HD, ed. Fractionation in radiotherapy. London: Taylor and Francis: 1987:1-21.
32. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689-694.
33. Manetti C, Le Doussal JM, Rouvier E, Gruaz-Guyon A, Barbet J. Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells. Int J Cancer 1995;63:250-256.
34. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997;276:122-126.